NCT03674138

Pharmacogenomic-Guided Antidepressant Drug Prescribing in Cancer Patients

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 99 (actual)
• Sponsor: H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, randomized clinical trial to investigate the clinical impact of a preemptive pharmacogenomics strategy to guide antidepressant therapy in cancer patients. Those enrolled onto the clinical trial will be randomized to either DNA-guided choice of therapy or clinical management alone. Scores on self-reported measures of depressive and anxiety symptoms along with quality of life will be compared between cohorts.

Conditions

• Depression
• Anxiety
• Generalized Anxiety Disorder
• Depressive Disorder
• Major Depressive Disorder
• Cancer

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	DNA-guided choice of therapy	Buccal swab for DNA genotyping to identify best antidepressant therapy
OTHER	Clinical management	Clinical management to identify best antidepressant therapy

Timeline

• Start date: 2018-09-12
• Primary completion: 2021-09-03
• Completion: 2024-10-27
• First posted: 2018-09-17
• Last updated: 2026-02-06

Locations

1 site across 1 country: United States